Nano Labs Ltd SEC Filings

Nano Labs is offering 5,952,381 Class A ordinary shares at $8.40 per share to institutional investors, along with warrants in a concurrent private placement. The warrants allow purchase of up to 5,952,381 additional shares at $10.00 per share, exercisable for 5 years.

Key offering details:

• Total gross proceeds: $50 million
• Placement Agent (Maxim Group) fee: 7% ($3.5 million)
• Net proceeds before expenses: $46.5 million
• Current stock price: $11.47 (as of June 26, 2025)

Important disclosures: The company operates through subsidiaries in China and Hong Kong, presenting unique risks. As a Cayman Islands holding company, investors don't directly hold equity in Chinese operations. The filing notes PCAOB inspection requirements, Chinese regulatory oversight risks, and potential delisting concerns under HFCAA. Cross-border fund transfers must comply with PRC regulations, with specific procedures for moving capital between subsidiaries.

Nano Labs Ltd (Nasdaq: NA) filed a Form 6-K to announce the pricing of a $50 million capital raise that combines (1) a registered direct offering of 5,952,381 Class A ordinary shares and (2) a concurrent private placement of warrants to purchase an equal number of shares. Each share-and-warrant unit is priced at $8.40, implying gross proceeds of roughly $50 million before placement fees and other transaction costs. The warrants become immediately exercisable, carry a five-year term from the effective registration date, and feature an initial exercise price of $10.00 per share, subject to standard anti-dilution adjustments.

Use of proceeds: Management states that net proceeds—together with any future cash generated from warrant exercises—will be deployed to acquire BNB (Binance Coin) as part of Nano Labs’ evolving digital-asset treasury strategy. No other operational or balance-sheet purposes were disclosed, suggesting a targeted move to increase exposure to cryptocurrency-denominated reserves rather than to fund working capital or R&D.

Structure & timing: The equity component is issued under the Company’s existing shelf registration statement (Form F-3 No. 333-273968), declared effective on 1 Sep 2023. The warrants and the ordinary shares issuable upon exercise are offered privately under Section 4(a)(2) and Regulation D and therefore remain unregistered. Closing is expected on or about 27 Jun 2025, subject to customary conditions. Maxim Group LLC serves as sole placement agent; its fees were not quantified.

Capital-market implications: Immediate dilution will equal the new share count issued (~5.95 million), plus potential future dilution should warrants be exercised. Based on typical free-float data for Nano Labs, the new issuance appears material, although the company did not disclose percentage dilution. The $1.60 spread between the unit price and the $10.00 strike offers investors potential upside yet limits immediate exercise likelihood, thereby postponing secondary dilution and cash inflow.

Strategic context: The decision to convert fresh capital directly into BNB marks an aggressive expansion of the firm’s Web 3.0 centric balance-sheet strategy. While alignment with its infrastructure focus could enhance ecosystem synergy, it also raises crypto-volatility risk and subjects treasury assets to market swings, regulatory scrutiny, and counter-party considerations relating to Binance.

Key takeaways for investors: (1) Nano Labs secures $50 million in near-term liquidity but at the cost of share dilution; (2) proceeds earmarked exclusively for a single crypto asset amplify financial-performance variability; (3) warrant terms could inject an additional $59.5 million (5.95 m × $10.00) of cash if exercised, contingent on future share-price appreciation.

Nano Labs Ltd (Nasdaq: NA) has filed Prospectus Supplement No. 2 to its May 2 2025 F-1 registration statement. The supplement incorporates two Form 6-K reports filed on 25 June 2025 and mainly addresses two capital-markets items:

• Resale prospectus – registration of 652,174 Class A ordinary shares issuable upon exercise of outstanding private-placement warrants dated 11 April 2024. Nano Labs will not receive proceeds from any share resale but would receive cash if warrant holders exercise. The warrants’ cash-exercise decision depends on the market price; the latest closing price (25 June 2025) was US$11.35.
• Convertible note financing – announcement of a US$500 million aggregate principal private placement of 360-day, zero-coupon, unsecured convertible promissory notes payable in cash or agreed cryptocurrencies (Bitcoin noted). Notes are convertible at the investors’ option at an initial US$20.00 per share (76% premium to the latest close), subject to usual anti-dilution adjustment. Repayment, if not converted, will be made in Bitcoin; pre-payment is prohibited. A change-of-control event triggers immediate repayment in Bitcoin.

The subscription period can span up to 360 days and may close in multiple tranches; the final amount could be less than US$500 million if not fully subscribed. As of 25 June 2025, Nano Labs completed an initial tranche of 600 BTC (≈US$63.6 million) and issued two notes. The company now holds 1,000 BTC in treasury. Management states the proceeds will fund business expansion, capital expenditure and general working capital.

The financing aligns with Nano Labs’ broader “BNB Treasury Strategy,” under which it aims to acquire up to US$1 billion in BNB and ultimately hold 5-10% of BNB’s circulating supply, subject to internal security and value assessments.

Warrant-related share resale, potential note conversion at a premium, and Bitcoin-denominated repayments introduce share-count and cryptocurrency-volatility considerations. All securities remain uncollateralised and high-risk; investors are referred to the Risk Factors section beginning on page 12 of the base prospectus.